drugset / Trial / NCT05063253
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy, safety, PK and PD characteristics of different doses of TG103 injection in overweight/obese subjects with type 2 diabetes mellitus.
Timeline
- Start
- 2021-10
- Primary completion
- 2024-03
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TG103 | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 22.5 mg | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 30 mg | Subcutaneous |